Viatris

VTRS

Market cap $17.2B

It can seem like a nothing-to-buy market. But there are solid stocks out there.

Viatris Inc. (VTRS) Q4 2025 Earnings Call Transcript

VTRS beats Q4 estimates on 5% revenue growth, boosted by strong Brands sales and Greater China gains, while returning over $1B to shareholders in 2025.

Viatris (VTRS) came out with quarterly earnings of $0.57 per share, beating the Zacks Consensus Estimate of $0.52 per share. This compares to earnings of $0.54 per share a year ago.

Although the revenue and EPS for Viatris (VTRS) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Drugmaker Viatris forecast annual profit below analysts' expectations on Thursday, after a fire at one of its major plants in India disrupted operations.

Reports Fourth-Quarter Total Revenues of $ 3.7B and Full-Year 2025 Total Revenues of $ 14.3B Meets or Exceeds 2025 Financial Guidance Across All Key Metrics[1] Returns More Than $1B to Shareholders in 2025; Expects Balanced Capital Allocation Approach for 2026 Provides 2026 Financial Guidance; Positioned for Sustainable Growth Anticipates Regulatory Decisions for Six Product Candidates in 2026 and Multiple Important Pipeline Milestones Completes Enterprise-Wide Strategic Review; Expects to Deliver $650M in Total Cost Savings With Reinvestment of up to $250M Over the Next 3 Years PITTSBURGH, Feb. 26, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced robust financial results for the fourth quarter and full year 2025. The Company also announced it has completed its enterprise-wide strategic review and expects to deliver meaningful net cost savings while enabling reinvestment in areas that enhance the growth profile and long-term competitiveness of the Company.

PITTSBURGH, Feb. 26, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that on February 23, 2026, its Board of Directors approved a 2026 dividend policy of 48 cents ($0.48) per share and declared a quarterly dividend of 12 cents ($0.12) for each issued and outstanding share of the Company's common stock. The dividend is payable on March 18, 2026, to shareholders of record as of the close of business on March 9, 2026.

FDA PDUFA Goal Date Set for October 17, 2026 PITTSBURGH, Feb. 25, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for MR-141 (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia. The FDA has assigned a PDUFA goal date of October 17, 2026.

Evaluate the expected performance of Viatris (VTRS) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.